COMMUNIQUÉS West-GlobeNewswire

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
14/05/2026
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development Robust reductions in tau [...]
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third [...]
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
14/05/2026
Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNI TM , as recognized by the WHO and USAN Phase II data in glabellar (frown) lines to be featured as a late- [...]
Ipsen présente la corabotase, un neuro-inhibiteur recombinant (RNI™) « premier de sa classe », lors du symposium SCALE
14/05/2026
La corabotase est la première molécule expérimentale d’une nouvelle classe de neuro-inhibiteurs recombinants, RNI TM , telle que reconnue par l’OMS et l’USAN* Les données de phase II concernant les rides glabellaires ( [...]
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
14/05/2026
MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, [...]
Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership to Advance AI-Powered Chronic Disease Care
14/05/2026
SHANGHAI, May 14, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Shanghai Tenry Pharmaceutical Co., Ltd. (“Tenry [...]
Memopezil Under Investigation: Evaluating the Claims, Risks and Hidden Official Website Complaints about the Natural Donepezil Cocoa and Honey Protocol
14/05/2026
Bacopa Monnieri, Rhodiola Rosea, L-Theanine, and Panax Ginseng in Memopezil Supplement Facts, Refund Policy, Ingredients, and Cognitive Support Claims Explained Largo, FL, May 13, 2026 (GLOBE NEWSWIRE) -- These [...]
JellyTide Claims Evaluated: The Gelatin Trick Recipe + Baking Soda Shot with Lemon for Weight Loss Using Jelly Tide Gummies
14/05/2026
JellyTide Scam or Legit? BHB Salts, Apple Cider Vinegar Gummies, Side Effects, Dosage, and 60-Day Guarantee Explained Largo, FL, May 13, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and [...]
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
13/05/2026
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3 [...]
Mdxhealth Reports Q1-2026 Results
13/05/2026
Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 ( GlobeNewswire ) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial [...]
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
13/05/2026
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its cash runway [...]
Glass House Brands Reports First Quarter 2026 Financial Results
13/05/2026
First quarter results include revenue of $40.5 million, average selling price of $171 per pound and biomass production of 152,000 pounds Company reiterates full year 2026 wholesale cannabis biomass production forecast [...]
Medicenna Announces the Launch of a Marketed Public Offering of Securities
13/05/2026
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a [...]
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
13/05/2026
Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 [...]
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
13/05/2026
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United [...]
Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
13/05/2026
REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for [...]
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE [...]
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
13/05/2026
On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan- [...]

Pages